No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ELAN240517C16000
- 1.25
- +0.15+13.64%
15min DelayTrading May 15 10:23 ET
1.25High1.25Low
1.25Open1.10Pre Close3 Volume127 Open Interest16.00Strike Price375.00Turnover0.00%IV0.06%PremiumMay 17, 2024Expiry Date1.29Intrinsic Value100Multiplier2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma13.30Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (CTKB), Elanco Animal Health (ELAN) and Atara Biotherapeutics (ATRA)
Global Bovine Respiratory Disease Treatment Strategic Business Report 2024-2030 Featuring Bayer, Bimeda, Boehringer Ingelheim, Ceva Sante Animale, Elanco, Merck, Vetoquinol, Virbac, & Zoetis
Elanco Animal Health Price Target Raised to $19.00/Share From $18.00 by Piper Sandler
Elanco Animal Health Price Target Raised to $19.00/Share From $18.00 by Piper Sandler
Piper Sandler Remains a Hold on Elanco Animal Health (ELAN)
U.S. Pledges Nearly $200M to Prevent Bird Flu Spread on Dairy Farms
Express News | NYSE Order Imbalance 103165.0 Shares on Sell Side
Comments
Elanco's CEO Jeff Simmons shows confidence in O'Neill's ability to deliver strategic value, citing her deep understanding of legal operations and regulatory compliance. O'Neill is excited about the company's growth and her role in shaping it.
Press Release: Elanco Appoints Shiv O'Neill as General Counsel and Corporate Secretary 1
Elanco's aqua business sale enables prioritization of investments in larger, more profitable markets, while enhancing balance sheet flexibility. The company is also targeting areas like monoclonal antibodies and other high-need emerging spaces.
Elanco shows dedication to robust corporate governance, emphasizing its commitment with leadership changes and improved shareholder rights. Its strategic plan, leveraging scale, diverse portfolio, and innovation, aims for growth and long-term shareholder value.
The low P/S ratio signals the investor sentiments of not expecting robust revenue growth. The underwhelming revenue outlook makes the company's stock less attractive, and any P/S increase would need an improvement in revenue prediction.
Analysts expect Elanco to become profitable within two years, but the company's growth rate may need to be very high to achieve this. Its high level of debt raises the risk associated with investing in the company.
Read more